Literature DB >> 7528922

Short-lived complexes between myelin basic protein peptides and IAk.

K Mason1, H M McConnell.   

Abstract

Kinetic rate constants and the equilibrium dissociation constant have been determined for the reaction between an affinity-purified class II major histocompatibility complex molecule IAk and a myelin basic protein analogue peptide, fluorescein-labeled Ac(1-14)A4C15. Under the experimental conditions used, the lifetime of the peptide-free IAk molecule with respect to inactivation is 3.1 hr. The equilibrium dissociation constant, 3.3 +/- 1.7 microM, is determined from measurements of the kinetics of peptide inhibition of IAk inactivation. The measured peptide dissociation halftime is relatively short, 30 min, and the deduced association rate is 100 M-1.s-1. The rate constants and the equilibrium constant are similar to those characteristic of kinetic intermediates in reactions of peptides and class II proteins that lead to long-lived terminal complexes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7528922      PMCID: PMC45458          DOI: 10.1073/pnas.91.26.12463

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  16 in total

1.  A first-order reaction controls the binding of antigenic peptides to major histocompatibility complex class II molecules.

Authors:  S N Witt; H M McConnell
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-15       Impact factor: 11.205

2.  Inhibition of experimental autoimmune encephalomyelitis by MHC class II binding competitor peptides depends on the relative MHC binding affinity of the disease-inducing peptide.

Authors:  M H Wauben; I Joosten; A Schlief; R van der Zee; C J Boog; W van Eden
Journal:  J Immunol       Date:  1994-04-15       Impact factor: 5.422

3.  A kinetic intermediate in the reaction of an antigenic peptide and I-Ek.

Authors:  S Sadegh-Nasseri; H M McConnell
Journal:  Nature       Date:  1989-01-19       Impact factor: 49.962

4.  Isolation and characterization of antigen-Ia complexes involved in T cell recognition.

Authors:  S Buus; A Sette; S M Colon; D M Jenis; H M Grey
Journal:  Cell       Date:  1986-12-26       Impact factor: 41.582

5.  Binding of immunogenic peptides to Ia histocompatibility molecules.

Authors:  B P Babbitt; P M Allen; G Matsueda; E Haber; E R Unanue
Journal:  Nature       Date:  1985 Sep 26-Oct 2       Impact factor: 49.962

6.  Kinetic intermediates in the reactions between peptides and proteins of major histocompatibility complex class II.

Authors:  C Beeson; H M McConnell
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

7.  Antigen presentation by supported planar membranes containing affinity-purified I-Ad.

Authors:  T H Watts; A A Brian; J W Kappler; P Marrack; H M McConnell
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

8.  Polymorphic residues on the I-A beta chain modulate the stimulation of T cell clones specific for the N-terminal peptide of the autoantigen myelin basic protein.

Authors:  C B Davis; D J Mitchell; D C Wraith; J A Todd; S S Zamvil; H O McDevitt; L Steinman; P P Jones
Journal:  J Immunol       Date:  1989-10-01       Impact factor: 5.422

9.  An autoantigenic T cell epitope forms unstable complexes with class II MHC: a novel route for escape from tolerance induction.

Authors:  P J Fairchild; R Wildgoose; E Atherton; S Webb; D C Wraith
Journal:  Int Immunol       Date:  1993-09       Impact factor: 4.823

10.  High affinity for class II molecules as a necessary but not sufficient characteristic of encephalitogenic determinants.

Authors:  M Wall; S Southwood; J Sidney; C Oseroff; M F del Guericio; A G Lamont; S M Colón; T Arrhenius; F C Gaeta; A Sette
Journal:  Int Immunol       Date:  1992-07       Impact factor: 4.823

View more
  8 in total

1.  Interpretation of biphasic dissociation kinetics for isomeric class II major histocompatibility complex-peptide complexes.

Authors:  T G Anderson; H M McConnell
Journal:  Biophys J       Date:  1999-11       Impact factor: 4.033

2.  Specific T cell recognition of kinetic isomers in the binding of peptide to class II major histocompatibility complex.

Authors:  J D Rabinowitz; K Tate; C Lee; C Beeson; H M McConnell
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

3.  Immunodominance of a low-affinity major histocompatibility complex-binding myelin basic protein epitope (residues 111-129) in HLA-DR4 (B1*0401) subjects is associated with a restricted T cell receptor repertoire.

Authors:  P A Muraro; M Vergelli; M Kalbus; D E Banks; J W Nagle; L R Tranquill; G T Nepom; W E Biddison; H F McFarland; R Martin
Journal:  J Clin Invest       Date:  1997-07-15       Impact factor: 14.808

4.  Stimulation of T cells by antigen-presenting cells is kinetically controlled by antigenic peptide binding to major histocompatibility complex class II molecules.

Authors:  H M McConnell; H G Wada; S Arimilli; K S Fok; B Nag
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

5.  Structural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition of peptide binding.

Authors:  H Kropshofer; A B Vogt; G J Hämmerling
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

6.  Early biochemical signals arise from low affinity TCR-ligand reactions at the cell-cell interface.

Authors:  C Beeson; J Rabinowitz; K Tate; I Gütgemann; Y H Chien; P P Jones; M M Davis; H M McConnell
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

7.  Functional HLA-DM on the surface of B cells and immature dendritic cells.

Authors:  S O Arndt; A B Vogt; S Markovic-Plese; R Martin; G Moldenhauer; A Wölpl; Y Sun; D Schadendorf; G J Hämmerling; H Kropshofer
Journal:  EMBO J       Date:  2000-03-15       Impact factor: 11.598

8.  An insulin peptide that binds an alternative site in class II major histocompatibility complex.

Authors:  S M Tompkins; J C Moore; P E Jensen
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.